Tag: Europe
-
Algae Feed Proposed to Enrich Farm Salmon Fatty Acids
A developer of feeds for farmed salmon says its algae-based feed supplements could arrest the sharp decline in omega-3 fatty acids discovered in a recent study.
-
Nanotech Material Found Having Anti-Bacterial Properties
A synthetic porous material developed to deliver drugs to the skin was shown in lab tests to prevent the growth of bacteria on its surfaces.
-
Trial Shows Antibody Reduces Days with Migraines
First results from a late-stage clinical trial shows a synthetic antibody reduces the number of days with migraines per month among people with episodic or infrequent migraines.
-
Infusion-to-Oral Drug Delivery Company Acquired
A company with a technology for converting drugs given by intravenous infusion into pills and capsules was acquired Grünenthal Group, a provider of pain medications.
-
Fertility Device Company Gains $9.7M in Early Funds
A two year-old medical device enterprise making a fertility tracker for women is raising $9.7 million in its first venture finance round.
-
Long-Acting Opioid Abuse Therapy Shown Working in Trial
An experimental long-acting drug was shown at least as effective, and in some cases superior, to the current standard of care for opioid use disorder.
-
Seedless Fruit Varieties Seen As Food Security Boost
A review of studies evaluating techniques for producing seedless fruit concludes these techniques can contribute to higher yields that help ensure the security of food supplies.
-
Oxford, Evotec Partner on Drug Discovery
A collaboration between University of Oxford and a German drug discovery company aims to speed promising new treatments to the market, including support for start-up enterprises.
-
Skin Patch Shown to Increase Peanut Tolerance in Children
A skin patch worn by children with peanut allergies was shown in a clinical trial to increase the wearers’ tolerance for peanuts by 10 times after 1 year.
-
Start-Up to Commercialize New Parkinson’s Treatment
Mavalon Therapeutics, a new company in the U.K., is being formed to bring a treatment to market that stops the progression of Parkinson’s disease.